RSS Ocugen Announces Positive Data From Retinitis Pigmentosa Study

Currently reading:
 RSS Ocugen Announces Positive Data From Retinitis Pigmentosa Study

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
12,181
Likes
1,923
Credits
33,750©
Cash
0$
Ocugen, Inc. (OCGN) announced an update on the safety and efficacy of its Phase 1/2 clinical trial for OCU400, aimed at treating retinitis pigmentosa, a condition affecting children and adults.

OCU400, a gene therapy that leverages the NR2E3 nuclear hormone receptor gene, has shown promising results in improving low-light visual acuity and demonstrating effectiveness across various genetic mutations.

The company also noted that the Phase 3 OCU400 liMeliGhT clinical trial remains on schedule, with a Biologics License Application (BLA) submission expected in the first half of 2026.

In pre-market trading, Ocugen's stock has risen by 1.58%, currently priced at $0.799 on the Nasdaq.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom